VITLNASDAQThe short version
Vital Farms, Inc.
Vital Farms is the leading U.S. pasture-raised egg brand, built on a network of 600-plus family farms. Revenue has compounded near 30% a year, but a 2026 commodity-egg shock cut profit guidance to near zero and put its free cash flow in question.
Public since July 2020 near $35, the stock fell to about $8 in 2022, ran above $52 in August 2025, then round-tripped to about $13 by mid-2026 — down roughly 75% while revenue kept climbing.
$12.95
Share price (Jul 10 2026)
$596M
Market cap
$759M
FY2025 net revenue
−75%
Off the Aug-2025 peak
SwipeScroll▾
The statements
Revenue more than quintupled since 2019; the cash line just went the other way
FY2020 → FY2025as reported · $
Revenue$759M+25%
Gross margin37.6%−0.3pp
Operating margin11.6%+1.2pp
Net income$66M+24%
EPS$1.44+22%
Free cash flow−$48M−$84M
Open the full statements →As reported, FY2020–FY2025. Growth and margins climbed; free cash flow turned sharply negative in the build year.
- Growth is the clearest fact. Net revenue climbed from $141M in 2019 to $759M in 2025 — roughly 32% a year — with gross profit rising in step to $286M.
- Margins turned real. Operating margin went from near zero in 2021–22 to a record 11.6% in 2025; net income reached $66M and diluted EPS $1.44.
- Free cash flow is the tell. After two positive years it swung to −$48M in 2025 as capex jumped to $82M for new capacity — the widest gap between profit and cash in the company's public life.
Cash conversion
Eight years of profit, six cents of it in cash — and a buyback at the top
$10.3M
8-yr cumulative free cash flowon $165.9M of net income
6¢
of free cash per $1 of profit, 2018–2025
$20M
Q1 buyback at $19.97/sharevs ~$13 today
Free cash flow was negative in three of eight years and never exceeded $40M in any of them.
- A company that turned $165.9M of eight-year net income into just $10.3M of free cash flow — about six cents on the dollar — and then burned $48.2M of FCF in FY2025 still repurchased $20M of stock at $19.97 a share in the same quarter it went cash-negative, halved cash-and-securities to $51.4M, and said it would start drawing its revolver.
- The other side. The repurchase was discretionary, funded from a debt-free balance sheet and reversible; $80M remains authorized, now deployable near book value of about $8 a share.
- Owner-cash cost. That single $20M buyback exceeds the $10.3M of free cash flow the business has produced across its entire eight-year public life — one quarter consumed more than eight years generated.
Category & moat
A 95% guide cut meets private label growing into the category Vital created
U.S. shell-egg volume share (%)
Private label's share grew roughly ten-fold since 2020 to about a third of Vital's; Vital's roughly tripled.
- The commodity-egg price collapse that cut Vital's FY2026 adjusted-EBITDA guide by 95% coincided with private-label pasture-raised share growing ten-fold to roughly a third of Vital's own share and the FY2025 10-K dropping the 88% category-share figure it had claimed in 2021 — signs the 2026 shock is structural encroachment, not only a cyclical trough.
- The other side. Vital is still the #1 U.S. pasture-raised brand and 2025's top volume-share gainer; management reads private label as expanding the category rather than taking branded share.
- Why it matters. If the premium is capped and margins settle mid-single-digit, normalized EPS lands near $0.18–$0.44 versus $1.54 in a full recovery — the hinge between cheap and value trap.
The stock
A full round trip: $35 to $52 to $13, while the business kept growing
Nasdaq close, 2020–2026. The multiple did most of the moving; the earnings base did not.
- Up, then down. Public in July 2020 near $35, the shares fell to about $8 in 2022, ran above $52 in August 2025, then collapsed toward $13 by mid-2026 — roughly 75% off the peak.
- The gap is the question. Revenue tripled and profit turned positive over the same years the stock round-tripped; it now trades near 9x record 2025 earnings and about 1.7x book.
- What re-rated it. A shift into a heavy build cycle — capex to $82M, free cash flow to −$48M — and a 2026 guide cut collided with the market's read on durable earnings power.
The industry
Pasture-raised is the one egg segment growing fast
U.S. egg segment volume growth, 2020–2025 (CAGR, %)
Consumers trading up within an everyday purchase — a mix shift, not a novelty spike.
- A structural shift. Eggs from hens with outdoor access rose from 5.7% of U.S. shell-egg volume in 2020 to 13.0% in 2025; the pasture-raised retail market reached about $1.3 billion.
- Long runway. Pasture-raised is still a sliver of the roughly $15.4 billion shell-egg category, and Vital reaches only about 10.5% of U.S. households against near-97% category penetration.
- A caution on the headline. The category's 21% dollar CAGR is inflated by avian-flu egg-price spikes; the durable signal is the volume mix shift, not the price-driven sales figure.
The growth plan
A $2 billion 2030 goal, now leaning on deeper baskets over new homes
U.S. household penetration (%)
Penetration more than doubled since IPO but flattened in 2025 — the year's ~25% revenue gain came from existing buyers.
- The target. Management guides to $2B of net revenue by 2030 at a 15–17% adjusted-EBITDA margin — about 21% annual growth, down from the ~32% compounded over 2019–2025.
- One lever doing the work. Store count has held near 24,000 since 2023 and penetration stalled at 10.5%, so growth now leans on buy rate; every non-core product has been discontinued.
- Capacity is in the ground. Egg Central Station alone carries over $1B of revenue capacity and a second plant opens in 2027, so the next leg is meant to be low-capex.
Ownership & control
Founder stepped off the board; insiders own under 4% — but bought the dip
Governance snapshot
| Item | Read |
|---|---|
| Founder O'Hayer stake | 16.3%, down from 27.4% at IPO; left board Feb 2026 |
| Officers + directors (15) | 3.9% combined; chair/CEO owns 1.9% |
| Chair + CEO | Combined in one person; lead independent director as counterweight |
| Related party | ~$2.46M paid in 2025 to a firm owned by the CEO's father |
| Insider buying | 13 open-market buys (~$0.6M) near $8–10 after the May crash |
- Concentration and a flag. The founder is now a passive holder and the CEO holds all three top roles; the board is staggered and pays the CEO's father's firm for plant project management.
- Alignment cuts the other way. After the ~75% drawdown a broad group of directors and officers bought stock on the open market in mid-May near $8–10 — eleven purchases in a single week.
- No dual class. Economic ownership equals voting power; the two big index funds, near 19% combined, are now the swing block on any vote.
Supply & biosecurity
Dispersed against disease, concentrated at one plant
600+
family farms — one flu hit is a fraction of capacity
0
Vital farms lost to avian flu in 2025
~79M
U.S. hens culled industry-wide, 2024–25
Disease risk is spread across the farm network; cost risk is concentrated downstream.
- Disease risk is spread thin. Eggs come from 600-plus small pasture farms, so a single avian-influenza outbreak is a fraction of a percent of laying capacity; no Vital farm was lost to the virus in 2025.
- But cost sits in one building. Nearly all eggs pass through a single Springfield facility, and gross margin is tethered to corn and soy feed — the commodity exposure a value buyer flags.
- Second plant coming. Vital Crossroads in Seymour, Indiana is expected fully operational in 2027, adding capacity and, until then, depreciation.
Channel concentration
About a quarter of revenue still flows through one distributor
Retail dollar sales by channel, 2025
Mainstream (Kroger, Publix, Target, Walmart)62%62%
Natural (Whole Foods, Sprouts)38%38%
The natural channel was 51% of retail dollars in 2019; mainstream is now the majority.
- The single dependency. UNFI, Whole Foods' primary distributor, has carried between 22% and 26% of net revenue — a counterparty chokepoint even as the customer base broadens.
- Diversifying underneath. Whole Foods fell from about 30% of retail sales in 2019 to 20% in 2025, while mainstream chains grew to 62% of retail dollars — reducing single-retailer risk over time.
2026 reset
Adjusted EBITDA guided from $114M to near zero in a single year
Adjusted EBITDA ($M)
The FY2026 guide was cut twice in ten weeks — from $105–115M in February to $0–10M in May.
- The mechanism. Commodity eggs fell to $0.10 a dozen, widening Vital's shelf-price gap; Q1 gross margin dropped to 28.3% from 38.5% and new-household trial slipped from 55%+ to 50%.
- Two readings, one number. Bulls see a cyclical air pocket that heals to double-digit margins by 2027; bears see peak-cycle economics resetting to mid-single digits. The evidence does not yet settle it.
- Solvency clears the screen. No term debt, about $111M of liquidity, a book floor near $8 — but cash more than halved to $51.4M in a quarter and management will start drawing the revolver.
Normalized value
The same revenue makes $0.18 or $1.54 — it turns on the margin
Implied normalized EPS by through-cycle margin
Structural reset (5% EBITDA margin)
$0.18
Partial heal (10%)
$0.86
Recovery (15%, 2025 level)
$1.54
Normalized revenue held near $820M. The spread is a sensitivity, widened by a fixed ~$30M depreciation and stock-comp bridge below EBITDA.
- Cheap or dear, same stock. At $12.95 that is roughly 8x earnings in the recovery case and more than 70x in the reset case — the valuation is most sensitive to where the through-cycle margin settles.
- The Street leans low. Consensus FY2027 EPS has been cut from $1.39 to $0.44 and the mean price target is $12 — pricing a partial, mid-single-digit heal, not a return to 15%.
- What settles it. Gross margin back toward 30% by late 2026 and a double-digit 2027 EBITDA margin would validate the recovery rows; a mid-single-digit stall makes today's price full.
Margin of safety
Cheap against peak earnings, dear against trough — the floor is asset value, not price
Price vs book and cash anchors ($/share)
At $12.95 the stock trades about 1.7x book; the tangible-asset floor sits well below today's price.
- What the price implies. To trade at a normal packaged-foods 10x EV/EBITDA, today's ~$526M enterprise value needs about $53M of normalized EBITDA — a mid-single-digit margin, between the trough and 2025's 15%.
- The debt-free balance sheet is a strength, not a floor. It removes solvency risk but does not stop the multiple compressing toward book if the recovery stalls, as the May-2026 low near book showed.
- The setup. A near-term-pain, later-gain shape is genuinely present; what remains unproven is that the later gain arrives as owner cash rather than another year of reinvestment.
What to watch
Cheap against peak earnings, dear against trough — the margin of safety rests on a recovery Vital cannot fully control.
- 01Gross margin back toward 30% by late Q4 2026, from 28.3% in Q1 — the sign the price gap is closing.
- 02FY2027 adjusted-EBITDA margin re-entering double digits — the 'later gain' showing up as profit, not another build year.
- 03Household penetration resuming its climb above 10.5% — flat penetration is the structural-reset tell.
- 04Buyback pace and the revolver draw — repurchases near $13 not $19.97, and covenant headroom as cash is drawn down.
This distills a guided study built chapter by chapter — the statements, the category, the cash, and what would change the read.
Compiled from the full report · 2026-07-11 · For information, not investment advice.